The author concluded that data on the effects of mood stabilisers and antipsychotics on weight change and metabolism in paediatric patients with bipolar disorder are limited. The evidence appeared to support these conclusions, but the limited search and other limitations of the review mean that they may not be reliable.
Participants included in the review
Studies of paediatric patients who had been diagnosed with a bipolar spectrum disorder were eligible for inclusion. In the included studies, the mean age of the patients was 12.3 years; most studies included patients aged 4 to 20 years but some only included adolescents or pre-school-aged children. In most studies patients had manic or mixed symptomatology.
Outcomes assessed in the review
Studies that assessed changes in body composition, glucose or lipid values were eligible for inclusion. Studies had to report numeric values for their measure of 'weight gain'.
How were decisions on the relevance of primary studies made?
The author did not state how the papers were selected for the review, or how many reviewers performed the selection.
Assessment of study quality
The author did not report any formal assessment of validity. However, aspects of methodological quality such as dropout rates, concomitant medications, measures used for weight-change outcomes, reporting of statistical significance and sample size were noted in the text.
Data extraction
The author did not state how the data were extracted for the review, or how many reviewers performed the data extraction. For each study, where possible, the weight gain plus a measure of variance and the p-value for the statistical significance of the treatment effect of the drug of interest compared with the control were tabulated.
Methods of synthesis
How were the studies combined?
The number of studies which reported statistically significant or clinically relevant changes in weight was reported; where possible, effect sizes were pooled across similar studies. Cohen's 'd' effect size was calculated for each subgroup. Pooled changes in weight were also apparently calculated for each subgroup. Other studies were combined in a narrative. 'Clinically relevant' was not defined in the review.
How were differences between studies investigated?
Differences between the studies were described in the narrative summary. The studies were grouped by intervention and duration of treatment. Differences between different drug groups were tested statistically using the F test, and pairwise comparisons were undertaken using Student's t-test.
Results of the review
Nineteen studies involving 24 individual drug trials were included (n=684): 4 RCTs (n=174), 11 open-label studies (n=458) and 4 chart reviews (n=52).
The drop-out rates ranged from 0 to 59% (mean 21). Only 5 studies prohibited or restricted concomitant medications. Twelve studies only reported absolute weight change. Nine studies did not report the results of tests of statistical significance.
Eighteen of the 24 individual trials reported a statistically significant or clinically relevant increase in weight. One study of lamotrigine (n=20) and one study of lithium (n=17) and lithium plus risperidone (n=21) reported no significant weight change at 8 weeks and 1 year, respectively. Three trials reported weight loss: two involved topirimate (n=9, and n=29 in an RCT) and one involved aripiprazole (n=14).
For short-term studies (mean duration 12 weeks or less), pairwise comparison showed significantly greater weight gain in patients receiving one second-generation antipsychotic plus mood stabiliser compared with those receiving one mood stabiliser (5.5 kg based on 32 patients in 2 trials versus 1.2 kg based on 171 patients in 6 trials, p<0.05; Cohen's d =2.32) or two mood stabilisers (2.1 kg based on 128 patients in 2 trials, p<0.05; Cohen's d = 2.17). The results were similar after excluding a study on topirimate. There were no significant differences for other pairwise comparisons.
The author stated that there were too few patients to pool weight change data for medium-and long-term trials.
Only two 8-week open-label trials systematically assessed changes in glucose and lipid levels. Neither reported any significant change in non-fasting glucose or lipid (n=31 treated with risperidone or olanzapine and n=30 treated with risperidone). The levels appeared to be non-fasting.
Authors' conclusions
Data on the effects of mood stabilisers and antipsychotics on weight change and metabolism in paediatric patients with bipolar disorder are limited. Weight gain appeared greater with antipsychotics plus mood stabilisers than with one or two mood stabilisers.
CRD commentary
The review addressed a clear question that was defined in terms of the participants, intervention and outcomes. Inclusion criteria for the study design were broad but this seems appropriate in view of the limited number of clinical trials identified. Only one database and references were searched and no attempts to minimise publication or language bias were reported. This might have resulted in the omission of other relevant studies and raises the potential for publication bias. Although some methodological flaws were mentioned, there was no formal assessment of validity, thus the results from these studies and any synthesis may not be reliable. The methods used to select studies and extract the data were not described, so it is not known whether any efforts were made to reduce reviewer error and bias. Pooled weight change data from similar studies were apparently calculated, but the methods used were not reported and it is not clear if the results were sufficiently similar for pooling to be appropriate. Comparisons between different drug
